FibroBiologics, Inc.
No SEC Form 4 filings for $FBLG in the last 30 days.
See all $FBLG insider activity →FibroBiologics (FBLG) received a U.S. patent for its fibroblast-based wound healing therapy. Preclinical studies showed faster healing, including in diabetic models. The stock is down 9.74% to $1.76.
FibroBiologics (FBLG) shipped a new batch of its experimental drug CYWC628 to Australia for a clinical trial on diabetic foot ulcers. The Phase 1/2 study evaluates safety, tolerability, and efficacy of the treatment. The company expects to report interim data in late 2026, with preclinical data suggesting potential for accelerated wound healing. FibroBiologics focuses on treatments for chronic diseases using fibroblast cells.
FibroBiologics (Nasdaq: FBLG) reported that its preclinical study showed cartilage repair in degenerative joints within four weeks of a single injection of chondrocyte spheroids. The company claims the therapy could offer a less invasive, lower-cost alternative to joint replacement, with a rapid four-day manufacturing process. FibroBiologics holds over 270 patents in various clinical pathways, including orthopedics.
Over the past 7 days, alphai's AI scored 2 news stories mentioning FBLG (FibroBiologics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent FBLG coverage spans technology, corporate actions and earnings.
The patent could strengthen the company's IP portfolio and support future product commercialization.
Trial supply logistics in Australia reduce operational risk and support the company’s timeline toward interim efficacy readout in 2H 2026.
Positive preclinical data may de‑risk the upcoming clinical program and support future financing.
Board addition may bring strategic connections but no immediate financial impact.
Preclinical cartilage-repair results and a fast four-day manufacturing claim can improve perceived pipeline quality, but they are not yet clinical proof.
alphai scores every news story that mentions FBLG with an AI model for sentiment and relevance, and aggregates insider trades from FibroBiologics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
FibroBiologics (FBLG) received a U.S. patent for its fibroblast-based wound healing therapy. Preclinical studies showed faster healing, including in diabetic models. The stock is down 9.74% to $1.76.
2 min readFibroBiologics (FBLG) shipped a new batch of its experimental drug CYWC628 to Australia for a clinical trial on diabetic foot ulcers. The Phase 1/2 study evaluates safety, tolerability, and efficacy of the treatment. The company expects to report interim data in late 2026, with preclinical data suggesting potential for accelerated wound healing. FibroBiologics focuses on treatments for chronic diseases using fibroblast cells.
3 min readFibroBiologics (Nasdaq: FBLG) reported that its preclinical study showed cartilage repair in degenerative joints within four weeks of a single injection of chondrocyte spheroids. The company claims the therapy could offer a less invasive, lower-cost alternative to joint replacement, with a rapid four-day manufacturing process. FibroBiologics holds over 270 patents in various clinical pathways, including orthopedics.
1 min readFibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 FibroBiologics Appoints Leigh Steinberg to Board of Directors Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, August 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a c
1 min readFibroBiologics (Nasdaq: FBLG) reported preclinical results for fibroblast-spheroid-derived chondrocyte spheroids (FSdCS) in animals with induced joint defects. According to the company, a single injection led to cartilage repair within four weeks. The company says FSdCS manufacturing takes four days and could support a lower-cost, scalable biologic alternative to joint replacement.
2 min readFibroBiologics (Nasdaq: FBLG) reported Q2 2026 results and said it dosed the first patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers. It completed cGMP manufacturing of three CYWC628 batches. The company raised $9.0 million via private placement and $3.0 million in a public offering. Q2 net loss was about $4.1 million, with cash of about $3.5 million at June 30, 2026.
4 min readFibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001958777 0001958777 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 02,
2 min readFibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 fblg-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 25, 2026, between FibroBiologics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the
4 min readFibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 fblg-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 FIBROBIOLOGICS, INC. 2026 EQUITY AND INCENTIVE COMPENSATION PLAN 1. Purpose . The purpose of this Plan is to permit award grants to Participants and to provide to such persons incentives and rewards for service and/or perform
2 min readFibroBiologics (NASDAQ:FBLG) said it has enrolled and dosed the first patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers. The multicenter randomized study in Australia will enroll up to 120 patients to test safety, tolerability, and efficacy versus standard of care, with an interim analysis after 6 weeks. The company previously guided interim results for Q3 2026.
4 min read
